Harmony Biosciences Holdings, Inc.

Equities

HRMY

US4131971040

Pharmaceuticals

Market Closed - Nasdaq 03:59:53 2024-02-23 pm EST 5-day change 1st Jan Change
32.5 USD +3.34% Intraday chart for Harmony Biosciences Holdings, Inc. -3.87% +0.62%
This article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In
Needham Cuts Price Target on Harmony Biosciences to $50 From $53, Maintains Buy Rating MT
Harmony Biosciences Holdings' Q4 Adjusted Net Income Falls, Net Product Revenue Rises; 2024 Revenue Guidance Issued MT
Transcript : Harmony Biosciences Holdings, Inc., Q4 2023 Earnings Call, Feb 22, 2024
Harmony Biosciences Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Harmony Biosciences Holdings, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Earnings Flash (HRMY) HARMONY BIOSCIENCES Posts Q4 EPS $0.73, vs. Street Est of $0.91 MT
North American Morning Briefing : Nvidia Ignites -2- DJ
Harmony Biosciences Says FDA Grants Priority Review for Wakix Supplemental New Drug Application MT
U.S. Food and Drug Administration Grants Priority Review to Harmony Biosciences' Application for WAKIX® in Pediatric Narcolepsy CI
Harmony Biosciences' Pitolisant Gets FDA's Orphan Drug Designation for Prader-Willi Syndrome MT
Harmony Biosciences Gets FDA Orphan Designation for Pitolisant in Prader-Willi Syndrome DJ
Mizuho Boosts PT on Harmony Biosciences to $42 From $33 Ahead of Q4 2023 Earnings Announcement, Maintains Buy Rating MT
Transcript : Harmony Biosciences Holdings, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-10-2024 05:15 PM
Harmony Biosciences Preliminary Q4 Results Show "Robust Momentum" for Narcolepsy-Related Drug, Oppenheimer Says MT
Goldman Sachs Adjusts Price Target on Harmony Biosciences Holdings to $28 From $25, Maintains Sell Rating MT
Harmony Biosciences Reports Higher Preliminary Q4 Revenue; Sets 2024 Revenue Outlook MT
Tranche Update on Harmony Biosciences Holdings, Inc.'s Equity Buyback Plan announced on October 31, 2023. CI
Harmony Biosciences Holdings, Inc. Provides Preliminary Revenue Guidance for the Fourth Quarter and Full Year 2023 and for the Year 2024 CI
BofA Securities Downgrades Harmony Biosciences Holdings to Underperform From Neutral MT
Harmony Biosciences Holdings, Inc. Announces Positive Topline Data from Phase 2 Signal Detection Study Evaluating Pitolisant in Adult Patients with Myotonic Dystrophy Type 1 CI
Harmony Biosciences Holdings, Inc. Appoints Peter Anastasiou as Class III Director and Member of the Compensation Committee of the Board CI
Mizuho Raises Price Target on Harmony Biosciences to $33 From $28 on 'Continued Commercial Execution', Reiterates Buy Rating MT
Raymond James Adjusts Price Target on Harmony Biosciences to $27 From $26, Maintains Outperform Rating MT
Harmony Biosciences Holdings' Q3 Non-GAAP Earnings, Revenue Rise MT
Transcript : Harmony Biosciences Holdings, Inc., Q3 2023 Earnings Call, Oct 31, 2023
Chart Harmony Biosciences Holdings, Inc.
More charts
Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical company. The Company is focused on developing and commercializing therapies for patients living with rare neurological diseases, as well as patients living with other neurological diseases who have unmet medical needs. Its product, WAKIX (pitolisant), is a molecule with a mechanism of action (MOA) specifically designed to increase histamine signaling in the brain by binding to H3 receptors. Its WAKIX is developed for the treatment of excessive daytime sleepiness (EDS) in adult patients with narcolepsy and treatment of cataplexy in adult patients with narcolepsy. Its narcolepsy treatment works primarily through histamine, a major wake-promoting neurotransmitter. The Company also provides HBS-102, an investigational compound, which is a melanin-concentrating hormone (MCH) receptor 1 (MCHR1) antagonist that targets MCH neurons in the brain. Its product candidates also include Zygel, which is a synthetic cannabidiol.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
8
Last Close Price
32.5 USD
Average target price
42.25 USD
Spread / Average Target
+30.00%
Consensus
1st Jan change Capi.
+0.62% 1 845 M $
+32.01% 693 B $
+21.62% 550 B $
+3.25% 390 B $
+18.74% 328 B $
+14.92% 315 B $
+7.97% 213 B $
-4.95% 212 B $
-3.58% 201 B $
-3.58% 157 B $
Other Pharmaceuticals
+229% on MICROSOFT CORPORATION since our purchase on January 11, 2019
Replicate our performance
fermer